Italian Study Notes Four Hepatitis B-Related Events in Switch

Hepatitis B reactivation remains rare in people with HIV who switch to injectable cabotegravir/rilpivirine, though clinical data presented at HIV Glasgow 2026 suggests providers must maintain rigorous monitoring protocols.

While large-scale cohort studies in Spain and Italy report low or non-existent reactivation rates, the transition away from regimens containing hepatitis B-active antiretrovirals creates a clinical window that requires careful assessment of immunity.

In Spain, the RELATIVITY cohort monitored 3,349 participants who switched to cabotegravir/rilpivirine before the end of 2024, with a median follow-up of 25 months, according to aidsmap. Researchers identified 115 individuals with isolated anti-HBc—a marker of past exposure—during this period. Despite the shift in medication, no cases of clinically suspected reactivation involving liver enzyme elevations were observed, noted Dr. Luz Martin Carbonero of University Hospital La Paz.

The Italian SCohoLART study tracked 627 people for a median of 2.7 years, aidsmap reported. Researchers observed four hepatitis B-related events, including one instance of symptomatic reactivation in a participant who had isolated anti-HBc at the time of the switch. This patient required hospitalization and a return to tenofovir-based treatment.

The Italian study highlighted that clinical safety does not rely solely on the switch itself, but on the underlying immune status of the patient. Three vaccinated participants who were anti-HBc negative at the time of their switch acquired hepatitis B during the follow-up period, aidsmap reported. Two of these individuals lacked detectable immunity despite prior vaccination, while one showed low levels of surface antibodies.

She emphasized that inducing or boosting surface antibodies does not guarantee protection against reactivation, necessitating a comprehensive risk assessment.

Forthcoming British HIV Association guidelines will recommend specific management steps for patients with isolated anti-HBc before switching treatments, according to aidsmap. For those who are HBsAg-negative and HBV-DNA negative, the protocol advises administering one dose of the hepatitis B vaccine followed by a re-test for anti-HBs levels after two weeks. If antibody levels remain below 10 IU/ml, patients should complete the full vaccine series before a switch is considered.

Data from the Italian study indicates that some individuals may fail to develop or maintain protective antibody levels despite vaccination. In these cases, the absence of a tenofovir-based regimen leaves them vulnerable to new acquisition.

University Hospital La Paz, which opened in 1964 as the first modern hospital center in Spain, has grown into one of the country’s largest facilities. Comprising 18 buildings across three major campuses, the institution serves a population of more than 500,000 people and functions as the clinical reference site for the Autonomous University of Madrid’s School of Medicine.

Experts recommend re-vaccination for individuals without detectable anti-HBs, particularly when their medical history regarding hepatitis B is incomplete or unavailable.